UPS has committed US$48 million to expand temperature-controlled logistics infrastructure across 27 facilities in Europe, Asia, and the Americas. The investment targets growing demand for biologics — projected to reach US$39.1 billion by 2033 — and addresses high-stakes cold-chain challenges, including up to 50% global vaccine waste from temperature failures. Leveraging acquisitions like Bomi Group and Andlauer Healthcare Group, UPS integrates regional expertise with global coordination. Its 19.2 million square feet of cGMP/GDP-compliant healthcare space spans over 200 countries and territories. Executives Kate Gutmann and John Bolla underscore the mission: ensuring reliable, compliant delivery of life-saving treatments.
According to businesschief.com, United Parcel Service (UPS) has committed US$48 million to expand its temperature-controlled logistics infrastructure across 27 facilities in Europe, Asia, and the Americas.
Targeted cold-chain infrastructure upgrade
The investment focuses on cross-dock facilities designed to optimise speed and short-term storage for air and ground movements. Products will be maintained within three distinct temperature ranges: 2–8°C for refrigerated goods, frozen capabilities, and 15–25°C for controlled room temperature shipments. UPS currently operates more than 19.2 million square feet of cGMP- and GDP-compliant healthcare distribution space globally — a network spanning over 200 countries and territories.
Response to biologics market growth
The expansion directly addresses rising demand for temperature-sensitive biologics, projected by Growth Market Reports to reach US$39.1 billion by 2033. PharmaSource data indicates that approximately one in three newly approved drugs is a biologic derived from living cells — and more than 85% of these require temperature-controlled handling throughout the supply chain. According to the World Health Organisation, temperature failures contribute to up to 50% of global vaccine waste, while associated annual losses from cold-chain failures are estimated at up to US$35 billion.
Strategic acquisitions and regional integration
The infrastructure build-out builds on recent strategic acquisitions: Bomi Group, Frigo Trans, and BPL in Europe, and Andlauer Healthcare Group in North America. UPS has also expanded its Incheon, Korea air hub to improve pharmaceutical trade flows between Asia and global markets. These moves integrate regional expertise and established customer relationships into UPS’s broader network — enabling coordinated compliance with diverse regulatory frameworks across jurisdictions.
Integrated control tower and accountability
To reduce handling risks inherent in fragmented networks, UPS employs a single integrated supply chain model. Its 24/7 control tower monitors shipments in real time, tracks environmental and logistical risks, and enables proactive intervention. John Bolla, President of UPS Healthcare, stated:
“Biologics and personalised treatments are driving better, more targeted care for patients.” — John Bolla, President of UPS Healthcare
He added:
“These investments reflect our commitment to strengthening our end-to-end supply chain that helps protect innovative treatments and diagnostics, supporting better patient outcomes.” — John Bolla, President of UPS Healthcare
Customer-aligned healthcare logistics mission
Kate Gutmann, Executive Vice President and President of International, Healthcare and Supply Chain Solutions at UPS, emphasized alignment with client needs:
“We have aligned our investments with our Healthcare customers’ specialised needs. Our global cross-dock facilities strengthen our end-to-end cold-chain capabilities to ensure critical treatments are delivered safely and reliably to patients around the world. This effort, and all of our work in healthcare logistics, extends from a deep understanding that we’re doing more than moving packages. We are helping patients access the medications and treatments they need.” — Kate Gutmann, EVP & President, International, Healthcare and Supply Chain Solutions, UPS
The initiative supports drug manufacturers expanding patient access across geographies with varying regulatory expectations — from the EU to Southeast Asia and the United States.
Source: businesschief.com
Compiled from international media by the SCI.AI editorial team.
